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Abstract
Background: The prognostic nutritional index (PNI) reflects immunonutritional status. We evaluated the effects of
postoperative PNI and perioperative changes in the PNI on overall survival (OS) in glioblastoma (GBM) patients.
Methods: Demographic, laboratory, and clinical data were retrospectively collected from 335 GBM patients.
Preoperative and postoperative PNIs were calculated from serum albumin concentration and lymphocyte count,
which were measured within 3 weeks before surgery and 1month after surgery. Patients were classified into high
(n = 206) or low (n = 129) postoperative PNI groups according to the postoperative PNI cutoff value and further
classified into four groups according to the cutoff values of the preoperative and postoperative PNIs, as follows:
Group HH (both high PNIs, n = 92), Group HL (high preoperative and low postoperative PNI, n = 70), Group LH (low
preoperative and high postoperative PNI, n = 37), and Group LL (both low PNIs, n = 136).
Results: The median OS was significantly longer in the high postoperative PNI (PNI ≥ 50.2) group than the low
postoperative PNI (PNI < 50.2) group (24.0 vs. 15.0 months, p < 0.001). In multivariate analysis, high postoperative
PNI was a significant predictor of OS. OS was significantly longer in Group HH than in Group LL and seemed longer
in Group HH than in Group HL and in Group LH than in Group LL. OS was not different between Groups HH and
LH or between Groups HL and LL.
Conclusions: High postoperative PNI was associated with improved OS and perioperative changes in PNI may
provide additional important information for prognostic prediction in GBM patients.
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Background
Glioblastoma (GBM) is the most common malignant
primary brain tumor characterized by high mortality and
recurrence. Despite the use of Stupp protocol (postoper-
ative radiotherapy plus concomitant and adjuvant temo-
zolomide chemotherapy), the median overall survival
(OS) is as short as 14.6 months [1, 2]. Moreover, there is
a survival gap even among patients who are managed
with the same treatment protocol. Numerous studies
have attempted to identify prognostic factors in GBM
patients. Well-documented prognostic parameters
associated with a favorable outcome in patients with
GBM include young age, high preoperative Karnofsky
performance status (KPS) score, genetic composition
(i.e., isocitrate dehydrogenase [IDH] mutation, O6-
methylguanine-DNA methyltransferase [MGMT] pro-
moter methylation), and more extensive surgical resec-
tion [3–15].
The prognostic nutritional index (PNI) is calculated
from the serum level of albumin and lymphocyte count
and reflects immunonutritional status [16]. Literature re-
views have revealed the controversy about the role of pre-
operative PNI in predicting the prognosis of GBM
patients [17–22]. However, no study has investigated the
prognostic significance of the postoperative PNI in GBM
patients. Moreover, the effects of combination of pre-
operative and postoperative PNIs on postoperative sur-
vival have not been studied in such patients. A few studies
focusing on the prognostic role of postoperative PNI have
reported that it is predictive of prognosis in patients with
hepatocellular carcinoma and lung cancer and a high
postoperative PNI is associated with a good prognosis in
such patients [23, 24]. These studies indicate that the
postoperative PNI rather than preoperative PNI can better
reflect postoperative general conditions in patients under-
going hepatic and pulmonary tumor surgeries. The post-
operative PNI may depend on postoperative clinical
course and management. Previous studies demonstrated
that postoperative complications had a negative relation-
ship with the postoperative PNI [23, 25].
Therefore, we hypothesized that a high postoperative
PNI would be associated with improved OS in GBM pa-
tients. This study evaluated the effects of the postopera-
tive PNI and the change in perioperative PNI on OS in
GBM patients and whether the postoperative PNI is a
significant prognostic factor. We also identified demo-
graphic and clinical factors that contribute to the prog-
nostic significance of postoperative PNI.
Methods
This retrospective study was conducted after approval
from the Institutional Review Board of Seoul National
University Hospital (number: 2101–092-1189). The In-
stitutional Review Board of Seoul National University
Hospital waived the requirement for written informed
consent because of the retrospective design of the study.
We included patients newly diagnosed with histological
GBM who underwent brain tumor surgery under general
anesthesia (total intravenous anesthesia with propofol
and continuous infusion of remifentanil) at Seoul Na-
tional University Hospital from 2010 to 2016. Exclusion
criteria were patients with surgical mortality, recurrent
GBM, missing data on preoperative or postoperative la-
boratory examinations, and infectious or chronic auto-
immune disease or glucocorticoid replacement, which
can affect the immune system and nutritional status. In
addition, patients with concurrent steroid use at the time
of PNI calculations were excluded.
Data collection
We retrospectively reviewed the electronic medical re-
cords of subjects to collect data categorized into four
parts: preoperative data, including demographic informa-
tion, comorbidities, daily activities, represented by the
KPS score, preoperative laboratory findings (serum albu-
min concentration and lymphocyte count); intraopera-
tive data, including surgical time and intraoperative
transfusions; postoperative data, including postoperative
laboratory findings (albumin levels and lymphocyte
count), KPS score at hospital discharge, the extent of
surgical resection, which was radiographically confirmed
and classified into gross total resection, near-total resec-
tion, subtotal resection, partial resection, and biopsy,
and postoperative adjuvant therapy (application and
completion of the Stupp protocol [1], radiotherapy only,
chemotherapy only, or none); and gene expression pro-
files, including MGMT methylation, epidermal growth
factor receptor amplification, and the IDH mutation.
Definition
The PNI was defined as 10 × albumin level (g/dL) +
0.005 × lymphocyte count (106/L) [16], and the preopera-
tive and postoperative PNIs were calculated from
preoperative (within 3 weeks before surgery) and postop-
erative (1 month after surgery but before postoperative
adjuvant therapy) laboratory findings, respectively. High
and low PNIs were defined when a PNI value was
greater than or equal to the optimal cutoff value of the
PNI and less than the optimal cutoff value, respectively.
OS was defined as the time interval from the date of
surgery to the date of death, or the date of the last
follow-up.
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate the
normality of the distributions of all continuous variables.
The Student’s t-test was used to analyze normal vari-
ables, and the Mann-Whitney U-test was used to
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compare skewed variables. Categorical variables were an-
alyzed using the chi-square or Fisher’s exact test. The
OS of GBM patients was analyzed using the Kaplan-
Meier method. Univariate analysis was first performed
to identify predictive factors of postoperative survival in
GBM patients. Variables with a p-value < 0.1 in univari-
ate analysis and well-known significant factors of
postoperative survival of GBM were entered into
multivariate logistic regression analysis with the forward
stepwise conditional method. Receiver operating charac-
teristic curve analysis were performed to identify the op-
timal cutoff values of the preoperative and postoperative
PNIs to predict OS. The optimal cut-off point was deter-
mined by maximizing the sum of sensitivity and specifi-
city (Youden’s index). To evaluate the effects of a change
in the perioperative PNI on OS, patients were reclassi-
fied into four groups according to the cutoff values of
the preoperative and postoperative PNIs: Group HH
(high preoperative PNI + high postoperative PNI group),
Group HL (high preoperative PNI + low postoperative
PNI group), Group LH (low preoperative PNI + high
postoperative PNI group), and Group LL (low preopera-
tive PNI + low postoperative PNI group). Differences in
OS among the four groups were analyzed using the
Kaplan-Meier method and the log-rank test. The alpha
value was adjusted with the Bonferroni correction to
compensate for multiple comparisons, and the statistical
significance of the alpha value was < 0.008 (0.05/6). The
relationships between preoperative and postoperative
PNIs and other clinical characteristics were evaluated
with the Pearson correlation test.
All statistical analyses were conducted using SPSS stat-
istical software for Windows, version 25.0 (IBM,
Armonk, NY, USA) and R version 4.0.3 (The R Founda-
tion for Statistical Computing, Vienna, Austria). A p-
value < 0.05 was considered significant.
Results
During the entire study period, 495 patients were diag-
nosed with histologically confirmed GBM. Among them,
160 patients (95 underwent surgery under local
anesthesia, two died, 44 were lost to follow-up due to
transfer to other local hospitals for postoperative adju-
vant therapy, and 19 had incomplete laboratory data re-
lated to the PNI) were excluded from the study. Finally,
335 patients were included in the data analysis.
The preoperative and postoperative PNIs revealed area
under the curve values of 0.579 (95% CI; 0.496–0.661;
P = 0.061) and 0.599 (0.522–0.676; P = 0.018) for OS, re-
spectively. The optimal cut-off values for the preopera-
tive and postoperative PNIs were 50.1 and 50.2,
respectively.
Patients in the high preoperative PNI group were
younger than those in the low preoperative PNI group,
and the high preoperative PNI group had a greater pro-
portion of male patients and patients with preoperative
and postoperative KPS score ≥ 70 than the low preopera-
tive PNI group. (Table 1). Patients were younger, more
patients had preoperative and postoperative KPS scores
≥70, underwent more frequent gross total resection of
GBM and completion of Stupp protocol in the high
postoperative PNI group.
A total of 233 (69.6%), 92 (27.5%), and 66 (19.7%) pa-
tients survived 1, 3, and 5 years after surgery, respect-
ively. Fifty-seven (17.0%) patients survived at the last
follow-up. The median (95% CI) OS of all patients was
19.0 (15.9–22.1) months. The duration of OS was signifi-
cantly longer in the high postoperative PNI group than
in the low postoperative PNI group (median OS: 24.0 vs.
15.0 months, P < 0.001, Fig. 1A) and longer in the high
preoperative PNI group than in the low preoperative
PNI group (median OS: 22.0 vs. 17.0 months, P = 0.008,
Fig. 1B).
Significant predictive factors for postoperative OS in
multivariate analysis (Table 2) were age < 60 years (odd
ratio [95% CI], 2.07 [1.02–4.21]; P = 0.045), high postop-
erative PNI (2.17 [1.14–4.10]; P = 0.018), MGMT pro-
moter methylation (2.61 [1.33–5.11]; P = 0.005), and
completion of the Stupp protocol (5.39 [2.18–13.27];
P < 0.001).
In subgroup analysis, OS was significantly longer in
the high postoperative PNI group than in the low post-
operative PNI group in patients who were male
(P < 0.001) and young (age < 60 years, P = 0.003), had
MGMT promoter methylation (P = 0.004), received gross
total resection of GBM (P = 0.001), had a postoperative
KPS score ≥ 70 (P = 0.005), and received postoperative
chemoradiotherapy, P = 0.001, Fig. 2A-F). OS was sig-
nificantly longer in the high preoperative PNI group
than in the low preoperative PNI group in patients who
were male and young, had an unmethylated MGMT
promoter, underwent gross total resection, had a pre-
operative KPS score ≥ 70 and postoperative KPS score <
70, and received adjuvant chemoradiotherapy (Supple-
mentary Fig. 1).
A significant difference in OS was observed among the
four groups (P = 0.001, Fig. 3). The median (95% CI) OS
durations were 24.0 (18.9–29.1), 15.0 (9.7–20.3), 24.0
(14.1–33.9), and 15.0 (11.2–18.4) months in Group HH
(n = 92), Group HL (n = 70), Group LH (n = 37), and
Group LL (n = 136), respectively. A significant difference
in OS was observed between Group HH and Group LL
(P < 0.001). OS was longer in Group HH than in Group
HL (P = 0.029), and in Group LH than in Group LL (P =
0.027). OS was not significantly different between
Groups HH and LH or between Groups HL and LL.
Both preoperative and postoperative PNIs showed sig-
nificant negative correlation with age (r = − 0.214 and −
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Table 1 Demographic, perioperative laboratory results, genetic, and postoperative treatment-related data
Preoperative PNI Postoperative PNI
Low (PNI < 50. 1)
(n = 173)
High (PNI ≥ 50. 1)
(n = 162)
P value Low (PNI < 50. 2)
(n = 206)
High (PNI ≥ 50. 2)
(n = 129)
P value
Age (yr) 56.5 ± 13.9 52.3 ± 13.7 0.005 57.2 ± 13.9 50.1 ± 12.9 < 0.001
< 60 96 (55.5%) 108 (66.7%) 0.047 108 (52.4%) 96 (74.4%) < 0.001
< 70 136 (78.6%) 148 (91.4%) 0.002 161 (78.2%) 123 (95.3%) < 0.001
Male gender (n) 91 (52.6%) 104 (64.2%) 0.041 114 (55.3%) 81 (62.8%) 0.218
BMI (kg/m2) 22.6 ± 3.2 23.5 ± 3.2 0.019 22.7 ± 3.2 23.6 ± 3.1 0.021
ASA physical status (n) 0.116 0.235
I 57 (32.9%) 63 (38.9%) 69 (33.5%) 51 (39.5%)
II 93 (53.8%) 88 (54.3%) 112 (54.4%) 69 (53.5%)
III 23 (13.3%) 11 (6.8%) 25 (12.1%) 9 (7.0%)
Comorbidity (n)
Hypertension 45 (26.0%) 46 (28.4%) 0.713 58 (28.2%) 33 (25.6%) 0.697
Diabetes mellitus 16 (9.2%) 9 (5.6%) 0.281 16 (7.8%) 9 (7.0%) 0.957
Cardiac disease 13 (7.5%) 6 (3.7%) 0.204 16 (7.8%) 3 (2.3%) 0.050
Respiratory disease 7 (4.0%) 4 (2.5%) 0.544 11 (5.3%) 0 (0.0%) 0.008
Liver disease 9 (5.2%) 8 (4.9%) 1.000 11 (5.3%) 6 (4.7%) 0.981
Renal disease 3 (1.7%) 0 (0.0%) 0.249 3 (1.5%) 0 (0.0%) 0.287
Cerebrovascular disease 12 (6.9%) 6 (3.7%) 0.285 10 (4.9%) 8 (6.2%) 0.777
Extracranial malignancy 11 (6.4%) 4 (2.5%) 0.113 12 (5.8%) 3 (2.3%) 0.177
Daily activity
Preoperative KPS score 80 (70–90) 90 (80–90) 0.009 85 (70–90) 90 (80–90) 0.023
≥ 70 (n) 144 (83.2%) 154 (95.1%) 0.001 177 (85.9%) 121 (93.8%) 0.040
KPS score at hospital discharge 90 (70–90) 90 (80–90) 0.024 90 (70–90) 90 (80–90) < 0.001
≥ 70 (n) 145 (83.8%) 146 (90.1%) 0.122 166 (80.6%) 125 (96.9%) < 0.001
Laboratory findings
Albumin (g/dL)
Preoperative 3.9 ± 0.4 4.4 ± 0.3 < 0.001 4.1 ± 0.4 4.3 ± 0.4 < 0.001
Postoperative 3.9 ± 0.4 4.1 ± 0.3 < 0.001 3.8 ± 0.4 4.3 ± 0.2 < 0.001
Delta (preoperative – postoperative) −0.01 ± 0.49 −0.26 ± 0.38 < 0.001 −0.23 ± 0.49 0.03 ± 0.35 < 0.001
Lymphocyte count (106/L)
Preoperative 1280.8 ± 495.2 2064.3 ± 667.6 < 0.001 1521.9 ± 646.7 1879.6 ± 736.3 < 0.001
< 1500 (n) 127 (73.4%) 37 (22.8%) < 0.001 116 (56.3%) 48 (37.2%) 0.001
Postoperative 1558.5 ± 646.7 1827.0 ± 578.6 < 0.001 1422.4 ± 466.5 2113.1 ± 621.4 < 0.001
< 1500 (n) 89 (51.4%) 47 (29.0%) < 0.001 120 (58.3%) 16 (12.4%) < 0.001
Delta (preoperative – postoperative) − 277.8 ± 680.1 237.3 ± 755.2 < 0.001 99.5 ± 702.4 −233.4 ± 808.5 < 0.001
PNI
Preoperative 45.5 ± 3.6 54.4 ± 3.2 < 0.001 48.2 ± 5.2 52.4 ± 5.3 < 0.001
Postoperative 46.8 ± 5.2 50.6 ± 5.1 < 0.001 45.4 ± 4.0 53.8 ± 3.0 < 0.001
Delta (preoperative – postoperative) −1.3 ± 5.8 3.8 ± 5.2 < 0.001 2.8 ± 5.9 −1.4 ± 5.3 < 0.001
Surgery time (hr) 4.4 ± 1.3 4.5 ± 1.4 0.581 4.4 ± 1.4 4.5 ± 1.2 0.471
Intraoperative transfusion (n) 41 (23.7%) 25 (15.4%) 0.077 54 (26.2%) 12 (9.3%) < 0.001
Tumor resection (n) 0.642 0.072
Gross total 102 (59.0%) 107 (66.0%) 0.220 119 (57.8%) 90 (69.8%) 0.037
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0.321, P < 0.001 in both). Preoperative PNI was positively
correlated with preoperative and postoperative KPS scores
(r = 0.221 and 0.147, P < 0.001 and P = 0.007 respectively)
but was not correlated with completion of the Stupp
protocol. Postoperative PNI was positively correlated with
preoperative and postoperative KPS scores and comple-
tion of the Stupp protocol (r = 0.231, 0.442, and 0.215,
P < 0.001 respectively). The delta PNI (preoperative PNI
– postoperative PNI) was negatively correlated with the
duration of OS in patients with mortality (r = − 0.160, P =
0.007). Also, the delta PNI was higher in patients with 1-
year and 3-year mortalities, compared with those with 1-
year and 3-year survivals (1-year: 2.2 ± 6.2 vs. 0.7 ± 5.9,
P = 0.029; 3-year: 1.6 ± 6.0 vs. 0.1 ± 6.0, P = 0.040).
Table 1 Demographic, perioperative laboratory results, genetic, and postoperative treatment-related data (Continued)
Preoperative PNI Postoperative PNI
Low (PNI < 50. 1)
(n = 173)
High (PNI ≥ 50. 1)
(n = 162)
P value Low (PNI < 50. 2)
(n = 206)
High (PNI ≥ 50. 2)
(n = 129)
P value
Near total 24 (13.9%) 16 (9.9%) 0.338 24 (11.7%) 16 (12.4%) 0.973
Subtotal 32 (18.5%) 28 (17.3%) 0.883 42 (20.4%) 18 (14.0%) 0.178
Partial 8 (4.6%) 7 (4.3%) 1.000 11 (5.3%) 4 (3.1%) 0.422
Biopsy 7 (4.0%) 4 (2.5%) 0.544 10 (4.9%) 1 (0.8%) 0.056
Gene expression profiles (n)
MGMT Promoter methylation* 97 (56.4%) 80 (50.0%) 0.291 110 (54.2%) 67 (51.9%) 0.774
EGFR amplification† 45 (26.0%) 41 (25.6%) 1.000 53 (25.9%) 33 (25.8%) 1.000
IDH mutation‡ 19 (12.2%) 30 (19.6%) 0.103 27 (14.4%) 22 (18.0%) 0.493
Postoperative new neurologic deficit (n) 43 (24.9%) 24 (14.8%) 0.031 54 (26.2%) 13 (10.1%) < 0.001
Postoperative treatment (n) 0.033 0.030
Stupp protocol 151 (87.3%) 151 (93.2%) 0.102 180 (87.4%) 122 (94.6%) 0.050
Completed 99 (57.2%) 104 (64.2%) 0.219 113 (54.9%) 90 (69.8%) 0.009
Chemotherapy 6 (3.5%) 5 (3.1%) 1.000 7 (3.4%) 4 (3.1%) 1.000
Radiotherapy 1 (0.6%) 3 (1.9%) 0.357 2 (1.0%) 2 (1.6%) 0.641
None 15 (8.7%) 3 (1.9%) 0.007 17 (8.3%) 1 (0.8%) 0.002
Data are expressed as number (proportion), mean ± standard deviation, or median (interquartile range). BMI body mass index, ASA American Society of
Anesthesiologists, KPS Karnofsky performance status, delta; preoperative –postoperative, PNI prognostic nutritional index, MGMT O6-methylguanine-DNA
methyltransferase, EGFR epidermal growth factor receptor, IDH isocitrate dehydrogenase. Data are expressed as number (proportion), mean ± standard deviation,
or median (interquartile range). *: n = 172 in preoperative PNI low group, n = 160 in preoperative PNI high group, and n = 203 in postoperative PNI low group. †:
n = 160 in preoperative PNI high group, and n = 205 in postoperative PNI low group, and n = 128 in postoperative PNI high group. ‡: n = 156 in preoperative PNI
low group, n = 153 in preoperative PNI high group, and n = 187 in postoperative PNI low group, and n = 122 in postoperative PNI high group
Fig. 1 Kaplan-Meier curves for cumulative survival according to (A) postoperative PNI and (B) preoperative PNI. PNI: prognostic nutrition index
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Discussion
Despite recent advancements in diagnostic and thera-
peutic techniques, GBM is associated with poor clinical
outcomes. Thus, it is relevant to identify potential prog-
nostic serum biomarkers for poor clinical outcomes in
GBM patients to help stratify patients. The PNI, which
is easily calculated from laboratory tests, is a simple, eco-
nomic, and convenient parameter for that purpose. This
is the first study to evaluate the effects of postoperative
PNI and perioperative changes in the PNI on prognosis
in patients with GBM. This study demonstrated that
high postoperative PNI was a significant independent
predictor of OS in GBM patients and the change in the
perioperative PNI helped predict the postoperative
prognosis.
In clinical practice, various nutritional indices incorp-
orating serum albumin concentration have been used to
reflect nutritional status including PNI, the albumin/
globulin ratio, and nutritional risk index [20, 23, 24, 26,
27]. PNI is an immunonutritional indicator. A recent
study demonstrated that nutritional status was associ-
ated with postoperative survival in patients with GBM,
and PNI rather than other nutritional indices robustly
reflected the nutritional status [22]. However, All previ-
ous studies investigating the relationship between the
PNI and prognosis of GBM focused only on the effect of
preoperative PNI on OS and reported inconsistent re-
sults [17–22]. In contrast with previous studies, we eval-
uated the prognostic significance of the postoperative
PNI in GBM patients and found a positive association
between postoperative PNI and OS. Since GBM is char-
acterized by rapid progression, quick and complete
surgical resection is the treatment of choice. In our
clinic, when a patient was suspected of GBM, the sur-
gery was performed as soon as possible. It took an aver-
age of 7 days, up to 10 days, from the visit of the
suspected patient to the surgery. Therefore, intensive
nutritional intervention was practically available in the
postoperative period in patients with GBM. Moreover,
we think that postoperative PNI can better reflect post-
operative general conditions than preoperative PNI and
that improving nutritional status just before starting
postoperative adjuvant therapy (for example, the Stupp
protocol) can be helpful in achieving a favorable
Table 2 Univariate and multivariate analysis for predictive factors associated with postoperative overall survival in glioblastoma
patients
Univariate analysis Multivariate analysis*
Odds ratio 95% CI P value Odds ratio 95% CI P value
Age < 60 years (n) 2.50 1.29–4.84 0.007 2.07 1.02–4.21 0.045
Male gender (n) 0.59 0.33–1.05 0.070
Preoperative KPS score≥ 70 (n) 1.07 0.42–2.69 0.891
KPS score at hospital discharge ≥70 (n) 3.11 0.93–10.43 0.066
Albumin (g/dL)
Preoperative 1.93 0.93–4.01 0.078
Postoperative 3.43 1.47–7.98 0.004
High preoperative PNI (PNI ≥ 50. 1) (n) 2.26 1.25–4.10 0.007
High postoperative PNI (PNI ≥ 50. 2) (n) 2.39 1.34–4.26 0.003 2.17 1.14–4.10 0.018
Extent of surgical resection 0.083
Gross total resection Reference
Near total resection 0.09 0.01–0.70 0.021
Subtotal resection 0.64 0.39–1.40 0.268
Partial resection 0.26 0.03–2.03 0.199
Biopsy 0.36 0.05–2.92 0.342
Postoperative new neurologic deficit (n) 0.61 0.27–1.35 0.220
Gene expression profiles (n)
MGMT Promoter methylation 2.62 1.40–4.89 0.003 2.61 1.33–5.11 0.005
IDH mutation 2.08 1.03–4.19 0.041
Completed Stupp protocol (n) 5.84 2.56–13.32 < 0.001 5.39 2.18–13.27 < 0.001
KPS Karnofsky performance status, PNI prognostic nutritional index, MGMT O6-methylguanine-DNA methyltransferase, IDH isocitrate dehydrogenase, RT radiation
therapy. *Multivariate analysis with the forward stepwise conditional method was performed and male gender, preoperative KPS score ≥ 70, KPS score at hospital
discharge ≥70, preoperative and postoperative serum albumin level, high preoperative PNI, the extent of surgical resection, postoperative new neurologic deficit,
IDH mutation, were adjusted. Nagelkerke R2 statistic in step 4 is 0.208
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Fig. 2 (See legend on next page.)
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outcome. For the reason, we chose postoperative PNI
and investigated its association with prognosis in pa-
tients with GBM.
In the present study, some results showed that the
postoperative PNI might take an advantage over the pre-
operative PNI in predicting prognosis in GBM patients.
First, a high postoperative PNI was an independent
prognostic factor for GBM in multivariate analysis,
whereas a high preoperative PNI was not. Second, the
high postoperative PNI was related to increased survival
in the subgroups of MGMT promoter methylation and
postoperative KPS score ≥ 70, while the high
preoperative PNI increased survival in the subgroups of
MGMT promoter unmethylation and postoperative KPS
score < 70. It is well known that MGMT promoter
methylation and high KPS score were associated with fa-
vorable outcomes in patients with GBM [3, 8, 10, 12,
13]. Third, a significant difference in OS was observed
among the four groups according to perioperative
changes in the PNI. In other words, patients in Group
HH (high preoperative and high postoperative PNI)
showed significantly better OS than those in Group LL.
OS was likely to be better in Group HH than Group HL,
and in Group LH than in Group LL. However, OS was
(See figure on previous page.)
Fig. 2 Kaplan-Meier curves for cumulative survival in subgroups. (A) male patients, (B) subjects who aged below 60, (C) patients with positive
MGMT promoter methylation, (D) patients who underwent gross total resection, (E) patients with postoperative KPS score≥ 70, and (F) patients
with adjuvant chemoradiotherapy. PNI: prognostic nutrition index; MGMT: O6-methylguanine-DNA methyltransferase; KPS: Karnofsky
performance status
Fig. 3 Kaplan-Meier curves for cumulative survival according to perioperative changes of PNI. PNI: prognostic nutrition index; Group HH: high
preoperative PNI and high postoperative PNI (solid line); Group LH: low preoperative PNI and high postoperative PNI (long dashed line); Group
HL; high preoperative PNI and low postoperative PNI (short dashed line); Group LL: low preoperative PNI and low postoperative PNI (dotted line).
Because Bonferroni correction of the alpha value was performed to compensate multiple comparisons, a p-value < 0.008 (0.05/6) was considered
statistically significant
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not significantly different between Groups HH and LH
or between Groups HL and LL. Similar to our results,
previous retrospective studies have demonstrated that
the combination of the preoperative and postoperative
PNI played an important role in predicting the precise
postoperative prognosis in patients with various malig-
nant tumors [25, 27, 28]. Moreover, the delta PNI
showed a significant negative correlation with the dur-
ation of OS in patients with mortality. Namely, it was
significantly higher in patients with 1-year and 3-year
mortalities than those without respectively. Finally, com-
pletion of the Stupp protocol was positively correlated
with postoperative PNI, not preoperative PNI. In this
study, completion of the Stupp protocol was the most
powerful predictor of favorable outcomes in patients
with GBM. Similarly, previous studies have been
highlighted the importance of completion of the Stupp
protocol in predicting a favorable prognosis in GBM pa-
tients [1, 2]. Taken together, our results suggest that al-
though both PNIs played a key role in predicting OS in
GBM patients, the postoperative PNI rather than the
preoperative PNI may provide more useful information
for predicting GBM prognosis.
An important component of the PNI is the serum level
of albumin, one of the simplest and most studied factors
representing nutritional status. The postoperative serum
level of albumin was associated with OS in GBM pa-
tients in univariate analysis, but it was not a predictor in
multivariate analysis. Previous studies investigating the
association between preoperative serum albumin con-
centration and prognosis of GBM reported that low
serum albumin concentration was an independent poor
prognostic factor [6, 29, 30]. Lymphocytes, which are the
other component of the PNI, play a key role in cell-
mediated immunity. Cell-mediated immunosuppression
is well documented in GBM patients [31, 32]. GBM itself
affects the number and function of T-lymphocytes.
Cancer-induced chronic inflammation is associated with
increased tumor proliferation and metastasis, and also
has an immunosuppressive effect with a reduced
lymphocyte count and impaired lymphocyte function
[33, 34]. Hematopoiesis of lymphocytes can also be af-
fected by nutritional status and anti-cancer treatment.
Their production in bone marrow significantly decreases
in patients who are protein malnourished [35, 36]. Post-
operative adjuvant radiotherapy and chemotherapy in-
hibit proliferation of hematopoietic progenitor cells and
block differentiation into lymphocytes, leading to lym-
phopenia. A previous clinical investigation reported a
close relationship between postoperative treatment-
related lymphopenia and a poor prognosis of GBM in
elderly patients [37]. Taken together, these findings sug-
gest that perioperative interventions, such as aggressive
nutritional support before surgery and during the early
postoperative period, may improve the prognosis of
GBM patients by increasing both of the PNIs.
In this study, the postoperative PNI was calculated
from serum albumin concentration and lymphocyte
count, which were measured at 1 month postoperatively
but before the commencement of postoperative adjuvant
therapy. The postoperative PNI reflected the immune-
nutritional status of the patients who had recovered
from the surgery and were ready for postoperative
adjuvant therapy (chemotherapy and/or radiotherapy).
Our results showed that postoperative PNI was posi-
tively correlated with postoperative KPS score and com-
pletion of the Stupp protocol. GBM patients with poor
nutritional status can have poor functional status and
decreased functional reserves to endure various postop-
erative surgical stress responses. Also, they can be vul-
nerable to the adverse effects of postoperative adjuvant
therapy, resulting in poor tolerance to adjuvant therapy
and subsequent poor clinical outcomes. Although the
Stupp protocol increases survival time, the standard
Stupp protocol might be too aggressive to be tolerable
for malnourished GBM patients. In this study, the inci-
dence of completed Stupp protocol was significantly
lower in patients with low postoperative PNI. In clinical
practice, when deciding on individualized postoperative
treatment options for patients with GBM, various factors
such as perioperative functional status, patient age,
immunonutritional status, and tolerability to the treat-
ment should be considered [38].
Our study had some potential limitations. First, as this
was a non-randomized retrospective study, there was a
possibility of unexpected selection bias. In addition, the
data were collected from a single institution. Second,
low Nagelkerke R2 values in multivariate analysis to pre-
dict postoperative survival suggest that clinically valid
prognostic parameters may have been omitted. Also, the
discrimination power of postoperative PNI as a single
predictive factor was poor. However, combined analysis
of preoperative and postoperative PNIs helped stratify
patients by providing the precise prognosis for patients
with GBM. Third, patients who underwent a GBM bi-
opsy under local anesthesia were excluded from the data
analysis because anesthetics can affect OS and disease-
free survival of various cancers [39, 40]. Therefore, cau-
tion is needed when interpreting our results.
Conclusions
In conclusion, a high postoperative PNI was associated
with improved postoperative OS in GBM patients. Com-
bined analysis of preoperative and postoperative PNIs
may provide additional supportive information on post-
operative prognosis in such patients. A further large-
scaled prospective study is needed to confirm our results
and determine whether perioperative interventions to
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increase both PNIs would improve the prognosis of
GBM patients.
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